Cantor Fitzgerald Maintains Buy Rating on HCA Healthcare with $444 Price Target

Cantor Fitzgerald maintains a Buy rating on HCA Healthcare with a price target of $444.00. The company's shares opened at $401.77. Analyst Sarah James, who covers the Healthcare sector, has a 57.50% success rate on recommended stocks. The analyst consensus is a Moderate Buy with an average price target of $396.69, a -1.26% downside from current levels.

HCA Healthcare Inc. (NYSE: HCA) reported robust financial results for the second quarter of 2025, with revenues increasing by 6.4% to $18.605 billion and net income rising by 13.1% to $1.653 billion. The company's diluted earnings per share (EPS) grew by 23.5% to $6.83 [1]. Operational highlights included a 1.8% increase in same facility admissions and a 1.3% rise in emergency room visits. Cash flows from operations more than doubled to $4.210 billion. Additionally, HCA declared a quarterly dividend of $0.72 per share and repurchased 7.031 million shares for $2.505 billion. The company raised its 2025 guidance, now expecting revenues between $74.00-$76.00 billion and diluted EPS of $25.50-$27.00 [1].

Analysts maintain a positive outlook on HCA Healthcare. Cantor Fitzgerald maintains a Buy rating with a price target of $444.00, while the analyst consensus is a Moderate Buy with an average price target of $396.69, a -1.26% downside from current levels [2]. Analyst Sarah James, who covers the Healthcare sector, has a 57.50% success rate on recommended stocks. The company's shares opened at $401.77 on July 2, 2025.

HCA Healthcare also announced its participation in the upcoming Wells Fargo 2025 Healthcare Conference, scheduled for September 4, 2025, at 2:15 PM ET. Investors and interested parties can access the live audio webcast and related presentation materials through HCA Healthcare's Investor Relations website [3].

References:
[1] https://www.stocktitan.net/news/HCA/
[2] https://www.stocktitan.net/news/HCA/
[3] https://www.stocktitan.net/news/HCA/